OncoCyte Corporation

NasdaqCM:OCX Rapporto sulle azioni

Cap. di mercato: US$50.5m

OncoCyte Performance dei guadagni passati

Il passato criteri di controllo 0/6

OncoCyte's earnings have been declining at an average annual rate of -3.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 11.1% per year.

Informazioni chiave

-3.3%

Tasso di crescita degli utili

21.0%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.0%
Tasso di crescita dei ricavi11.1%
Rendimento del capitale proprio-159.2%
Margine netto-3,597.7%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oct 28
Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Aug 30

Revisiting OncoCyte Corp.

May 04

Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?

Jan 25
Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?

OncoCyte signs an at-the-market agreement to sell $50M of common stock

Jun 14

Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt

Jun 02
Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt

Ripartizione dei ricavi e delle spese

Come OncoCyte guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqCM:OCX Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 241-371210
31 Mar 241-40139
31 Dec 232-26149
30 Sep 231-22168
30 Jun 231-17187
31 Mar 231-11207
31 Dec 221-19227
30 Sep 22-1-22142
30 Jun 220-34163
31 Mar 221-43193
31 Dec 212-44205
30 Sep 215-352910
30 Jun 214-282610
31 Mar 212-262311
31 Dec 201-30229
30 Sep 201-322210
30 Jun 200-30209
31 Mar 200-26198
31 Dec 190-22157
30 Sep 190-19135
30 Jun 190-17116
31 Mar 190-1696
31 Dec 180-1696
30 Sep 180-1587
30 Jun 180-19127
31 Mar 180-18117
31 Dec 170-19127
30 Sep 170-19117
30 Jun 170-1477
31 Mar 170-1376
31 Dec 160-1156
30 Sep 160-1266
30 Jun 160-1165
31 Mar 160-1055
31 Dec 150-945
30 Sep 150-724
30 Jun 150-514
31 Mar 150-514
31 Dec 140-514

Guadagni di qualità: OCX is currently unprofitable.

Margine di profitto in crescita: OCX is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: OCX is unprofitable, and losses have increased over the past 5 years at a rate of 3.3% per year.

Accelerare la crescita: Unable to compare OCX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: OCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendimento del capitale proprio

ROE elevato: OCX has a negative Return on Equity (-159.19%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate